cas 21962-45-8|| where to buy 4-formyl-3-methoxybenzonitrile

Nom du produit:4-formyl-3-methoxybenzonitrile

IUPAC Name:4-formyl-3-methoxybenzonitrile

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM156985-500g	in stock	șňňň

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 21962-45-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:21962-45-8; Formule moléculaire:C9H7NO2; Point de fusion:-; Code SMILES:N#CC1=CC=C(C=O)C(OC)=C1; Densité:

: Numéro de catalogue:CM156985; Poids moléculaire:161.16; Point d'ébullition:318.2°C at 760 mmHg; N° Mdl:MFCD07779491; Stockage:Keep in a tight container and store at 2°C~8°C

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Finerenone; Bayer announced that FINEARTS-HF met its primary endpoint, achieving a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as hospitalizations for HF or urgent HF visits. The randomized, double-blind, placebo-controlled, parallel-group, multi-center phase III cardiovascular outcomes study evaluated the efficacy and safety of KERENDIA® (finerenone) for investigational new use in patients with HF with a LVEF≥40% (left ventricular ejection fraction). Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that was approved to reduce the risk of cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, sustained eGFR decline, and end-stage kidney disease in adult patients with CKD associated with T2D.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.